Sanofi takes €100M charge after Dengvaxia analysis leads it to seek smaller label

29th November 2017 Uncategorised 0

After an analysis showed that Sanofi’s highly touted dengue vaccine could lead to more serious infections if used in the wrong setting, the company is requesting a label change that will likely lead to fewer eligible recipients. With the development, Sanofi is taking a €100 million ($119 million) charge in the fourth quarter.

More: Sanofi takes €100M charge after Dengvaxia analysis leads it to seek smaller label
Source: fierce